3:45 – 4:25pm

Burning Issues in GERD

SPEAKER
C. Prakash Gyawali, MD

Presenter Disclosure Information

The following relationships exist related to this presentation:

► C. Prakash Gyawali, MD, MRCP: Research support from Covidien/Given Imaging; Consulting for Abbvie, Covidien, Quintiles; Speakers’ Bureau for Abbvie, Ironwood.

Off-Label/Investigational Discussion

► In accordance with pmICME policy, faculty have been asked to disclose discussion of unlabeled or unapproved use(s) of drugs or devices during the course of their presentations.

Burning Issues in Gastroesophageal Reflux Disease (GERD)

C. Prakash Gyawali, MD
St. Louis, USA

Learning Objectives

• Discuss the pathophysiology and changing epidemiology of GERD
• List the various treatment options for patients with GERD
• Evaluate the complications and extra esophageal manifestations of GERD

Case Presentation 1

47-year-old male with worsening heartburn

• Reports almost daily post-prandial symptoms in spite of daily omeprazole 20 mg
• Nocturnal heartburn can awaken him from sleep
• Denies weight loss, anorexia, nausea or vomiting, difficulty swallowing or painful swallowing
• Has gained 20 pounds over the past year but otherwise his health is unchanged

Lab work 4 months ago:
• Normal CBC and CMP

Physical exam:
• White male
• Normal vital signs
• BMI 31.2 kg/m²

Reason for appointment:
• He heard that heartburn can lead to cancer
• He also wants to know if there are any more effective treatments

CBC=complete blood count; CMP=complete metabolic panel; BMI=body mass index
GERD: Definitions

“symptoms or complications resulting from the reflux of gastric contents into the esophagus, oral cavity (including larynx) or lung”

“a condition that develops when the reflux of gastric content causes troublesome symptoms or complications”

ESOPHAGEAL SYNDROMES

Symptomatic Syndromes
- Typical reflux syndrome
- Reflux chest pain syndrome
- Esophagitis
- Stricture
- Barrett’s esophagus
- Adenocarcinoma

Syndromes with injury
- Cough
- Laryngitis
- Asthma
- Dental erosions

Proposed associations
- Pharyngitis
- Sinusitis
- Idiopathic pulmonary fibrosis
- Recurrent otitis media

EXTRA-ESOPHAGEAL SYNDROMES

Established associations
- Cough
- Laryngitis
- Asthma
- Dental erosions

Factors Responsible for the Changing Epidemiology of GERD

- Aging population
- Increasing prevalence of obesity
- Use of drugs that affect LES pressure and gastric emptying
- Self-treatment / access to OTC medications?
- Dietary habits, other lifestyle factors?

LES=lower esophageal sphincter

Higher BMI Increases Risk of GERD Symptoms

- Even moderate weight gain among persons of normal weight can cause or worsen reflux symptoms
- Weight loss is associated with a decreased risk of symptoms

Study of 2306 women with at least weekly GERD symptoms and 3904 with no symptoms

Multivariate odds ratio for reflux symptoms

Body mass index (kg/m²)

Factors Leading to GERD

- Saliva
- Hypomotility mechanism
- LES dysfunction
- Hiatal hernia
- Downstream factors


Diagnosis of GERD

Is there a gold standard?

1. Endoscopy?
2. Barium studies?
3. pH monitoring?

GERD

“Typical” symptoms

- Heartburn
- Burning feeling from stomach to neck
- Regurgitation
- Belching

If heartburn is the only or chief symptom the likelihood of GERD is 60-75%

A presumptive diagnosis of GERD can be established in the setting of typical symptoms of heartburn and regurgitation. Empiric medical therapy with a proton pump inhibitor (PPI) is recommended in this setting.

Upper Endoscopy in GERD: Advice from the American College of Physicians

- Alarm Features
  - Dysphagia, bleeding, anemia, weight loss, vomiting
- Persistent symptoms despite PPI BID for 4-8 weeks
- Severe erosive esophagitis after 8 weeks of PPI (to assess healing & rule out Barrett’s esophagus)
- History of esophageal stricture with recurrent dysphagia

Other indications:
- Men >50 years with >5 years of GERD symptoms & other risk factors, including:
  - nocturnal GERD, hiatal hernia, obesity, smoking, intra-abdominal fat
- Surveillance of Barrett’s esophagus

PPI = proton pump inhibitor

LA classification of erosive esophagitis

LA Grade A
≥1 isolated mucosal breaks <5 mm long

LA Grade B
≥1 isolated mucosal breaks >5 mm long

LA Grade C
≥1 mucosal breaks bridging the tops of folds but involving <75% of the circumference

LA Grade D
≥1 mucosal breaks bridging the tops of folds and involving >75% of the circumference

Diagnostic Testing for GERD cont’d

- pH monitoring
  - Useful for refractory GERD symptoms and chest pain
- Multichannel intraluminal impedance
  - Helpful for diagnosis in non-acidic reflux
- Esophageal manometry
  - Useful in evaluation of dysphagia and chest pain in selected patients

Accuracy of Short-Term High-Dose PPI Trial* in Diagnosing Pathological Reflux

*The “omeprazole test” – 40 mg PO QAM and 20 mg PO QPM for 1 week

Fass R et al. Arch Intern Med. 1999

Sensitivity Specificity Accuracy

PP: proton pump inhibitor

Diagnostic Testing for GERD

Barium swallow
Upper gastrointestinal series
- Useful to detect anatomic abnormalities (e.g. hiatal hernia, achalasia, stricture)
- Does NOT play a role in GERD diagnosis

Accuracy:
Severe esophagitis: 80%
Mild esophagitis: 25%
Barrett’s: 26%

Reflux of barium during the study:
Seen in 25-75% of GERD pts
Falsely seen in 20% normals

Endoscopy Negative Disease

A heterogenous group of disorders presenting as typical GERD symptoms in the absence of visible esophageal injury at endoscopy

Non-Erosive Reflux Disease (NERD)
"The presence of typical GERD symptoms due to intraesophageal acid exposure in the absence of visible esophageal injury at endoscopy".

Functional Heartburn (Rome III)
- Burning retrosternal pain or discomfort
- Absence of evidence that GERD is the cause of symptoms
- Absence of histopathology-based esophageal motility disorders

What is Non-Erosive Reflux Disease?

What is Barrett’s esophagus?

Prevalence of Barrett’s Esophagus in GERD Patients

Some Facts About Extra-Esophageal GERD

What is Barrett’s esophagus?

Squamous Mucosa

Intestinal Metaplasia

Prevalence of Barrett’s Esophagus

378 patients with GERD
94% men, 86% Caucasian
Median age: 56 yrs

BE
Long BE
Short BE

13%
5%
8%
When to suspect GERD in asthma

- Adult onset asthma
- Poor response to asthma therapy
- Nocturnal cough
- Worsening asthma:
  - big meal, alcohol, supine position

Comparison of typical and atypical GERD

<table>
<thead>
<tr>
<th></th>
<th>Typical</th>
<th>Atypical</th>
</tr>
</thead>
<tbody>
<tr>
<td>Symptoms</td>
<td>Heartburn/</td>
<td>Pulmonary/laryngeal</td>
</tr>
<tr>
<td></td>
<td>regurgitation</td>
<td></td>
</tr>
<tr>
<td>Pathophysiology</td>
<td>Transient</td>
<td>Multi-factorial</td>
</tr>
<tr>
<td></td>
<td>relaxation of LES</td>
<td></td>
</tr>
<tr>
<td>Endoscopy findings</td>
<td>Common</td>
<td>Uncommon</td>
</tr>
<tr>
<td>pH findings</td>
<td>High sensitivity</td>
<td>Lower sensitivity</td>
</tr>
<tr>
<td></td>
<td>High specificity</td>
<td></td>
</tr>
<tr>
<td>Treatment response</td>
<td>Excellent</td>
<td>Less predictable</td>
</tr>
</tbody>
</table>

Management of GERD in 2015

Impact of Lifestyle Changes on GERD: What is the Evidence?

16 trials examined effectiveness of lifestyle changes

<table>
<thead>
<tr>
<th>Lifestyle change</th>
<th>Effect</th>
</tr>
</thead>
<tbody>
<tr>
<td>Weight loss</td>
<td>Improved pH-metry results and symptoms</td>
</tr>
</tbody>
</table>

Management of GERD

- Weight loss is recommended for GERD patients who are overweight or have had recent weight gain.
- Head of bed elevation and avoidance of meals 2 – 3 h before bedtime should be recommended for patients with nocturnal GERD.

PPIs vs H2RAs vs Placebo for Erosive Esophagitis (EE)

On-Demand vs. Continuous PPI Therapy for GERD

- 176 patients with NERD or Grade I/II esophagitis and frequent relapses treated with rabeprazole 10 mg

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Response (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Continuous</td>
<td>86%</td>
</tr>
<tr>
<td>On-demand</td>
<td>75%</td>
</tr>
</tbody>
</table>

P = 0.065

Bour et al. Aliment Pharm Ther 2005;21:805

Management of GERD

- An 8-week course of PPIs is the therapy of choice for symptom relief and healing of erosive esophagitis.
- Non-responders to PPI should be referred for evaluation.
- In patients with partial response to PPI therapy, increasing the dose to twice daily therapy or switching to a different PPI may provide additional symptom relief.


Extraesophageal presentations of GERD: Asthma, Chronic cough and Laryngitis

- A PPI trial is recommended to treat extraesophageal symptoms in patients who also have typical symptoms of GERD.


PPI therapy: When is more better?

- Recent studies suggest that twice daily PPI controls intraesophageal acid exposure no better than once daily PPI in patients with GERD
- Daily PPI therapy controls intraesophageal acid exposure better than every other day PPI
- Sustained symptom response with daily PPI therapy is inversely related to BMI
- In obese patients with erosive esophagitis, twice daily PPI may provide better symptom relief than once daily PPI


Extraesophageal presentations of GERD: Asthma, Chronic cough and Laryngitis

- GERD can be considered as a potential co-factor in patients with asthma, chronic cough, or laryngitis. Careful evaluation for non-GERD causes should be undertaken in all of these patients.
- A diagnosis of reflux laryngitis should not be made based solely upon laryngoscopy findings.


LARS vs. Esomeprazole for Chronic GERD: 3 Year Analysis from the LOTUS Trial

- Open, parallel group study in 11 European sites
- 412 patients with chronic GERD (EE & response to PPI) randomized to LARS or esomeprazole 20 mg/day
- PPI dose escalation allowed
- Primary outcome: % of patients remaining in remission at 3 years
- 23% required increased PPI dose over time
- No between-group differences in improvement of microscopic esophagitis

LARS = laparoscopic antireflux surgery

Surgical options for GERD

- Surgical therapy is a treatment option for long-term therapy in GERD patients.
- Surgical therapy is generally not recommended in patients who do not respond to PPI therapy.


Potential Safety Risks of PPIs

<table>
<thead>
<tr>
<th>Safety Issue</th>
<th>Clinical Significance</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cytochrome P450 interaction</td>
<td>Negligible</td>
</tr>
<tr>
<td>Cisplatin interaction</td>
<td>Probable</td>
</tr>
<tr>
<td>Clostridium difficile infection</td>
<td>Probable</td>
</tr>
<tr>
<td>Other infections</td>
<td>Probable</td>
</tr>
<tr>
<td>Rebound hypersecretion</td>
<td>Negligible</td>
</tr>
<tr>
<td>Fractures</td>
<td>Unclear</td>
</tr>
<tr>
<td>Idiosyncratic reactions (AIN, hepatitis)</td>
<td>Rare</td>
</tr>
<tr>
<td>Anaphylaxis</td>
<td>Rare</td>
</tr>
<tr>
<td>Pregnancy</td>
<td>Likely negligible</td>
</tr>
<tr>
<td>Hypomagnesemia</td>
<td>Rare (seen with &gt; 1 year treatment)</td>
</tr>
</tbody>
</table>


Warnings Added to PPI Labels in 2012

<table>
<thead>
<tr>
<th>Safety Issue</th>
<th>Clinical Significance</th>
</tr>
</thead>
<tbody>
<tr>
<td>Interaction with clopidogrel</td>
<td>Concomitant use of clopidogrel reduces pharmacologic activity of clopidogrel. Avoid coadministration with PPIs.</td>
</tr>
<tr>
<td>Clostridium difficile associated diarrhea</td>
<td>Should be considered for diarrhea that does not improve.</td>
</tr>
<tr>
<td>Concomitant use with methotrexate (primarily at high dose)</td>
<td>PPI use may elevate and prolong serum levels of methotrexate and/or its metabolite, possibly leading to methotrexate toxicity. Temporary withdrawal of PPI may be considered.</td>
</tr>
</tbody>
</table>


Heartburn: More Than One Disease

- Pathological acid reflux
- Non-acid reflux
- Disturbed motility
- Visceral hypersensitivity / brain-gut interactions
  - Chemical, osmolar, mechanical
- Psychological abnormalities
  - Somatoform disorder


Potential risks with PPI use

- Patients with known osteoporosis can remain on PPI therapy. Concern for hip fractures and osteoporosis should not affect the decision to use PPI long-term except in patients with other risk factors for hip fracture.
- PPI therapy can be a risk factor for Clostridium difficile infection and should be used with care in patients at risk.


Emerging Therapeutic Agents for GERD

- Acid inhibitors
  - Longer-acting PPIs
    - eg. ilaprazole, tenatoprazole, AGN-201904–2
  - P-CABs (potassium-competitive acid blocker)
- Reflux inhibitors
  - GABA-B agonists, mGlyR5 modulators
- Pain modulators
  - Antidepressants, melatonin, TPRV1 antagonists
- Prokinetics

None of these drugs are currently FDA approved for GERD
Management of GERD: Summary

• Prevalence of GERD and its complications are increasing
• PPIs are the most effective medical therapy
  • Minimum effective dosing should be utilized
  • BID dosing is common but offers little incremental benefit over QD dosing
• Surgery in expert hands provides another highly effective treatment option for GERD
  • Novel procedures and devices deserve further study
• A variety of emerging therapies are in development for patients with GERD symptoms